The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

AFL great, turned Cerutty Macro Fund portfolio manager, Chris Judd is with HP Rx founder and managing partner Hashan De Silva for today’s Talk Ya Book.

They discuss CurveBeam AI (ASX:CVB), a company in which Mr De Silva is a director. Mr De Silva holds 565,493 ordinary shares, millions of options and 320,928 indirect shares.

The company’s developed a CT scanning device, called HiRise, that works when a patient is weight-bearing, providing imaging while patients are standing. The images can be done within an orthopaedic centre, and release lower radiation levels.

CurveBeam has a market cap of $36 million and was trading at 16 cents (May 28).

KP Rx invests in a diverse range of biotech, medical device, diagnostic, and health tech companies located predominantly in Australia and New Zealand. It is backed by Karst Peak Capital.

Talk Ya Book was created by Chris Judd in 2019 as a show where fund managers could share their highest conviction investment idea but more importantly showcase their investment framework to the public.

Disclaimer: Juddcorp Pty Ltd ACN 635 629 631 is a corporate authorised representative (CAR) (CAR Number 1300536) of Boutique Capital Pty Ltd ACN 621 697 621 AFSL 508011.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online

Alligator Energy: Perfectly positioned for next wave of Aussie uranium production

Global powers everywhere are grappling with decarbonisation and energy security, especially as nuclear power has transitioned from a side discussion to a central

Mink Ventures defines nickel-copper massive sulphide mineralisation in Ontario

Author: Dr Ryan D. Long

Patrys begins key activities for delirium candidate

Patrys has commenced key manufacturing and regulatory activities for a candidate being developed to alleviate delirium.

EVE Health Group to target global markets with reformulated drugs

EVE Health Group will test global markets after successfully completing R&D work on several reformulated drug…